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ABSTRACT
By enzymatically hydrolyzing the terminal phospho-
diester bond at the 30-ends of DNA breaks,
tyrosyl-DNA phosphodiesterase (Tdp1) repairs
topoisomerase-DNA covalent complexes and
processes the DNA ends for DNA repair. To
identify novel Tdp1 inhibitors, we developed a
high-throughput assay that uses electrochemilumi-
nescent (ECL) substrates. Subsequent to screening
of 1981 compounds from the ‘diversity set’ of the
NCI-Developmental Therapeutics Program, here we
report that furamidine inhibits Tdp1at low
micromolar concentrations. Inhibition of Tdp1 by
furamidine is effective both with single- and double-
stranded substrates but is slightly stronger with the
duplex DNA. Surface plasmon resonance
studies show that furamidine binds both single-
and double-stranded DNA, though more weakly
with the single-stranded substrate DNA. Thus, the
inhibition of Tdp1 activity could in part be due to the
binding of furamidine to DNA. However, the inhibi-
tion of Tdp1 by furamidine is independent of the
substrate DNA sequence. The kinetics of Tdp1
inhibition by furamidine was influenced by the
drug to enzyme ratio and duration of the reaction.
Comparison with related dications shows that
furamidine inhibits Tdp1 more effectively than
berenil, while pentamidine was inactive. Thus,
furamidine represents the most potent Tdp1
inhibitor reported to date.
INTRODUCTION
Discovered by Nash and coworkers in 1996, tyrosyl DNA
phosphodiesterase I (Tdp1) belongs to the phospholipase
D superfamily of phospholipids hydrolyzing enzymes
(1,2). Functionally, Tdp1 is part of the DNA repair
complex that resolves the irreversible topoisomerase I
(Top1)-DNA cleavage complexes by catalyzing the
hydrolysis of 30-phosphotyrosyl bonds (3). In addition
to the removal of peptides bound via a 30 phosphotyrosyl
linkage, Tdp1 can catalyze the cleavage of other chemical
bonds such as a phosphohistidine bond (4). Tdp1 can also
remove a 30-phosphoglycolate or biotin-linked substrate
and act at 30-abasic sites (4,5). Tdp1 thus participates in
the repair of a variety of 30 adducts/base damages from
DNA. An interaction of Tdp1 with DNA ligase III (6)
and XRCC1 (7), members of the base excision repair
(BER) complex has also been demonstrated. More
recently, Tdp1 has also been implicated in the repair of
topoisomerase II (Top2)-mediated DNA damage as
bacterially expressed yeast Tdp1p processed the 50
phosphotyrosyl linkage of a peptide derived from yeast
Top2 covalently to DNA (8). Therefore, Tdp1 may
function in multiple DNA repair pathways.
Tdp1 is physiologically important since a point muta-
tion in the TDP1 gene causes the neurological disorder
called spinocerebellar ataxia with axonal neuropathy
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camptothecin (CPT), a potent Top1 inhibitor (6,10,11).
Moreover, overexpression of a human or yeast Tdp1
fusion protein has been shown to alleviate some of the
eﬀects of CPT treatment (12,13). These observations
suggest that inhibitors of Tdp1 could act synergistically
with CPT in a combined anticancer therapeutic regimen.
Additionally, hypersensitiveness to CPT in Tdp1-defective
yeast was conditional to deﬁciencies in the checkpoint
(Rad9) and 30-endonucleases (Mus81/Eme1) pathways
(14–16). Thus, in principle, therapeutic selectivity can
be achieved by combining Top1 and Tdp1 inhibitors as
a signiﬁcant number of tumors have defective DNA repair
and checkpoint pathways (17).
As Tdp1 inhibitors in association with Top1 inhibitors
could confer a selective advantage for cancer chemother-
apy, we began searching recently for Tdp1 inhibitors
(18). Currently, the only reported inhibitors of Tdp1
are vanadate, tungstate, aminoglycoside antibiotics and
ribosome inhibitors (18,19). Our initial aim was to develop
a high-throughput assay that would provide a sensitive,
reliable and a rapid method to screen chemical libraries
for novel Tdp1 inhibitors.
Here, we report the development of a sensitive high-
throughput electrochemiluminescent (ECL) assay to
identify novel inhibitors of Tdp1. Identiﬁed by the ECL
assay, the dication furamidine (DB75, NSC 305831) was
further studied to determine its molecular interactions
with recombinant Tdp1 and its DNA substrates.
MATERIALS AND METHODS
Drugs and reagents
The 1981 compounds of the diversity set were obtained
from the Developmental Therapeutics Program (DTP)
of the National Cancer Institute (NCI), NIH. Berenil
and Pentamidine were purchased from Sigma-Aldrich
(St. Louis, MO, USA). High-performance liquid
chromatography-puriﬁed oligonucleotides and tyrosyl
nucleotides were purchased from the Midland Certiﬁed
Reagent Co. (Midland, TX, USA).
Preparation of human Tdp1
Human Tdp1 expressing plasmid pHN1910 (a gift from
Dr Howard Nash, Laboratory of Molecular Biology,
National Institute of Mental Health, National Institutes
of Health) was constructed using vector pET-15b
(Novagen, Madison, WI, USA) with full-length human
Tdp1 and an additional His-tag sequence of
MGSSHHHHHHSSGLVPRGSHMLEDP in its N termi-
nus. The His-tagged human Tdp1 was puriﬁed from
Novagen BL21 cells using chelating sepharose
TM fast ﬂow
column (Amersham Biosciences, Piscataway, NJ, USA)
according to the company’s protocol. The collected
fractions were assayed immediately for Tdp1 activity.
Fractions that showed Tdp1 activity were pooled and
dialyzed in 20% glycerol, 50mM Tris-HCl, pH 8.0,
100mM NaCl, 10mM b-mercaptoethanol and 2mM
EDTA. Dialyzed samples were aliquoted and stored at
 808C. Tdp1 concentration was determined using the
Bradford protein assay (Bio-Rad Laboratories, Hercules,
CA, USA). Tdp1 purity was determined as a single
 70kDa band representing over 95% of the detectable
proteins stained by Coomassie after SDS–polyacrylamide
gel electrophoresis (SDS-PAGE).
High-throughputelectrochemiluminescent assay
Our electrochemiluminescent (ECL) assay is based on the
BioVeris (BV) ECL technology developed by BioVeris,
Inc. (Gaithersburg, MD, USA). ECL is based on the use
of ruthenium labels (BV-TAG
TM), designed to emit light
when stimulated. These labels, together with a speciﬁc
instrumentation (M-SERIES Analyzer), provided our
platform for biological measurements. This technology
has been successfully applied to drug discovery, pharma-
ceutical industry, clinical and industrial detection (20,21).
The present report is the ﬁrst application of the ECL
biotechnology to Tdp1.
Preparation ofthe ECL BV-14Y substrate
The 50-biotinylated 14Y DNA substrate (sequence shown
in Figure 3A) was obtained from Midland Certiﬁed
Reagent and coupled to an NHS ester BV-Tag (BioVeris
Inc.) to generate the ECL substrate BV-14Y. Coupling
was achieved by incubating 175mlo f5 0-biotinylated 14Y
DNA at 200mM in phosphate buﬀered saline (PBS),
pH 7.4 with 25ml of NHS-ester BV-Tag (BioVeris Inc.)
at 3mg/ml in 100% dimethyl sulfoxide (DMSO). After
30min at room temperature under agitation, the coupling
reaction was loaded onto a mini Quick Spin Oligo column
(Roche Diagnostics, Indianapolis, IN, USA) pre-
equilibrated with 3 volumes of PBS, pH 7.4 containing
0.075% (w/v) sodium azide (Sigma-Aldrich, St. Louis,
MO, USA). The recovered fraction was aliquoted and
stored at  208Ca t1 0mM in PBS.
Linking ofthe ECL substrate tostreptavidin magnetic beads
A substrate stock solution for 500 reactions was prepared
by mixing 40mlo f1 0 mM ECL BV-14Y substrate with
500ml of streptavidin magnetic beads (Dynabeads M-280,
BioVeris Inc.) and incubating for 30min at 258C under
constant agitation. After magnetic separation and a
two-volume wash with the Tdp1 assay buﬀer (50mM
Tris-HCl, pH 8.0, 80mM KCl, 2mM EDTA and 1mM
DTT), the linked ECL substrate was resuspended in 500ml
of assay buﬀer at a concentration of 800nM. The linked
ECL substrate can be stored at 48C for up to a month
without loss of activity.
ECLassay
The linked ECL BV-14Y substrate at a concentration of
0.8nM was incubated with 1nM Tdp1 in the absence or
presence of the drugs (10mM) to be tested. Reactions were
carried out in 96-well plates at a ﬁnal volume of
100ml/well in assay buﬀer for 60min at 378C. The
reactions were stopped by adding 1 volume of stop
buﬀer (25mM MES pH 6.0). Plates were read with an
M-SERIES M8 analyzer (BioVeris Inc.) and the ECL
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(GraphPad Software, San Diego, CA, USA).
Preparation ofTdp1 substrates forgel assays
High-performance liquid chromatography-puriﬁed oligo-
nucleotides 14Y (see Figure 3A) (7) and 14Y-CC (see
Figure 5A) were labeled at their 50-end with [g-
32P]ATP
(PerkinElmer Life and Analytical Sciences, Boston, MA,
USA) by incubation with 30-phosphatase-free T4 poly-
nucleotide kinase (Roche Diagnostics, Indianapolis, IN,
USA) according to the manufacturer’s protocols.
Unincorporated nucleotides were removed by Sephadex
G-25 spin-column chromatography (mini Quick
Spin Oligo columns; Roche Diagnostics). For the
production of the oligonucleotide duplexes D14Y, the
32P-radiolabeled 14Y oligonucleotide was mixed with
the complementary oligonucleotide (see Figure 3A) at
equal molar ratios in annealing buﬀer (10mM Tris-HCl,
pH 7.5, 100mM NaCl, and 10mM MgCl2), heated to
968C, and allowed to cool down slowly (over 2h) to room
temperature.
Tdp1 gelassays
Unless indicated otherwise, Tdp1 assays were performed
in 20ml mixtures in Tdp1 assay buﬀer (see above)
plus 40mg/ml bovine serum albumin. Twenty ﬁve
nanomolar 50-
32P-labeled substrate (14Y or 14Y-CC or
D14Y) was reacted with 1ng of Tdp1 (0.7nM) in the
absence or presence of inhibitor for 20min at 258C.
Reactions were stopped by the addition of 60ml of gel
loading buﬀer [96% (v/v) formamide, 10mM EDTA, 1%
(w/v) xylene cyanol and 1% (w/v) bromphenol blue].
Twelve-microliter aliquots were resolved in 20% denatur-
ing polyacrylamide (AccuGel; National Diagnostics,
Atlanta, GA, USA) (19:1) gel containing 7M urea. After
drying, gels were exposed overnight to PhosphorImager
screens (GE Healthcare Bio-Sciences Corp., Piscataway,
NJ, USA). Screens were scanned, and images were
obtained with the Molecular Dynamics software.
Densitometry analyses were performed using the
ImageQuant 5.2 software (GE Healthcare Bio-Sciences
Corp., Piscataway, NJ, USA). Tdp1 activity was deter-
mined by measuring the fraction of substrate converted
into 30-phosphate DNA product by densitometry analysis
of the gel image (3). Figures show representative results
that were consistently reproduced at least three times.
Surface plasmonresonance analysis
Binding experiments were performed on a Biacore 2000
instrument (Biacore Inc., Piscataway NJ, USA). 50
biotinylated stem-loop (biotin-GATCTAAAAGACTT
TCTCAAGTCTTTTAGATC) and single-stranded oligo-
nucleotides (biotin-GATCTAAAAGACTT) were syn-
thesized by IDT (Coralville, IA, USA). Stem-loop
oligonucleotides were annealed by heating to 908C for
5min followed by snap cooling on ice for 15min.
Biotinylated oligonucleotides were immobilized to
neutravidin-coated sensor chips as described previously
(22). Approximately 5000 RU’s of neutravidin was
attached to all ﬂow cells on the sensor chips.
Oligonucleotides were reconstituted in buﬀer consisting
of 10mM Tris, pH 7.5, 300mM NaCl and 1mM EDTA.
Single-stranded and stem-loop oligonucleotides were
injected over ﬂow cell 2 and 4, respectively until
approximately 500 RU’s of oligonucleotide were captured
on the chip surface. Furamidine was diluted into running
buﬀer [10mM MES, 100mM NaCl, 1mM EDTA, 5%
DMSO (v/v) pH 6.25] and injected over all ﬂow cells at
20ml/min at 258C. Following compound injections, the
surface was regenerated with a 10s 1M NaCl injection
followed by a 10s running buﬀer injection. A DMSO
calibration curve was included to correct for refractive
index mismatches between the running buﬀer and
compound dilution series. Data was analyzed using the
Scrubber software version 2 (David Myszka, University of
Utah) and the equilibrium binding of furamidine was ﬁt to
either a single-site or two-site steady state binding model
(Figure 4C and D). The equation used to ﬁt the single-site
steady state binding model was:
B ¼
RmaxF
KD þ F
þ NS F
where B¼bound complex, Rmax¼total concentration of
ligand, F¼total concentration of analyte, NS¼non-
speciﬁc binding and KD¼equilibrium dissociation con-
stant. The equation used to ﬁt the two-site steady state
binding model was:
B ¼
Rmax 1F
KD1þ F
þ
Rmax 2F
KD2þ F
þ NS F
where B¼sum of bound species for the two types of
complex, Rmax1 and Rmax2¼total concentration to the
two species of ligand, F¼total concentration of analyte,
KD1 and KD2¼equilibrium dissociation constants for the
two types of bound complex and NS¼non-speciﬁc
binding.
RESULTS
Novel high-throughput electrochemiluminescent (ECL)
assayto screen forTdp1 inhibitors
To discover inhibitors of Tdp1, we developed a novel ECL
high-throughput assay (for details see Materials and
Methods section and Figure 1). An ECL substrate
for Tdp1 was generated after coupling a ruthenium-
containing tag (BV-Tag) to the 30-end of a 14-mer
oligonucleotide with a 50-biotin and a 30-tyrosyl moiety
(Figure 1A) (3,7). In the presence of Tdp1, the tyrosyl-
bound BV-Tag is hydrolyzed from the ECL substrate (BV-
14Y DNA) and washed away, leading to a loss of the
electroluminescent signal (Figure 1B and C). In this assay,
a potential Tdp1 inhibitor would be detected as preventing
this loss of signal with a level of signal retention reﬂective
of the potency of the putative inhibitor. Thus, in our high-
throughput ECL assay, active compounds were identiﬁed
as restoring to the control levels (without Tdp1) the signal
lost in the presence of Tdp1.
Using the high-throughput ECL assay, we screened the
‘Diversity Set’ from the Developmental Therapeutics
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Figure 1. High-throughput electrochemiluminescene assay developed to identify novel Tdp1 inhibitors. (A) Generation of the electrochemilumi-
nescent (ECL) substrate (BV-14Y). The ruthenium-containing tag (NHS ester BV-Tag; from BioVeris Corp.) is coupled to the 30-end of the tyrosyl-
containing DNA substrate [14Y (sequence as in 3A) linked to a biotin at its 50 end]. After coupling, the BV Tag is attached to the phosphotyrosine of
the 14Y DNA forming the BV-14Y DNA after the release of a succinimide group. (B) Processing of the ECL substrate by Tdp1. The ECL substrate
BV-14Y bound to magnetic beads was generated as described in the Materials and Methods section. Upon addition of Tdp1, the tyrosine-BV-Tag
group is hydrolyzed away leaving behind a 30 phosphate on the DNA bound to the beads. After stopping the reactions, the samples are analyzed by
the ECL analyzer. During the analysis, only the magnetic beads are retained in the analysis chamber by magnetic ﬁeld while the rest of the sample is
washed away. In the absence of Tdp1, the ECL signal is maximum as the BV-14Y DNA is retained on the magnetic beads. Upon addition of Tdp1,
the tyrosine-BV-Tag group is cleaved away resulting in the loss of ECL signal (arrow). Potential Tdp1 inhibitors prevent this loss of signal. (C) Signal
response curve in the presence of increasing concentrations of Tdp1. The ECL signal is lost when the Tdp1 concentration is increased.
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recombinant human Tdp1. The diversity set consists of
1981 compounds representative of the chemical/structural
diversity of the available repository of more than 140000
chemicals (for details, see http://dtp.nci.nih.gov/branches/
dscb/diversity_explanation.html). Of the 1981 compounds
from the DTP diversity set, 169 positive hits were
identiﬁed as inhibiting at least 70% of the Tdp1 activity
at a ﬁxed concentration of 10mM (Figure 2A). Subsequent
analyses as HPLC to evaluate chemical purity of the
samples reduced the number of potential inhibitors of
Tdp1 to 69 compounds. Further testing in gel-based
assays led to the identiﬁcation of 49 compounds as
conﬁrmed Tdp1 inhibitors. Thus,  8% of the NCI-DTP
diversity set (1981 chemicals) were active against Tdp1at
10mM drug concentration in the ECL high-throughput
assay. This assay is therefore a sensitive and eﬃcient
technique for the screening of novel Tdp1 inhibitors.
The diamidine NSC 305831 (for structure, see
Figure 2B), more commonly known as furamidine
(DB75) (23), was among the most potent inhibitors of
Tdp1 with complete restoration of the normal Tdp1 signal
in the ECL assay (see Figure 2A). Furamidine was chosen
among other positive hits because it belongs to a very
interesting group of compounds. Furamidine and closely
related heterocyclic amines are currently under clinical
investigation as anti-parasitic agents (24). DB289, an
orally available methamidoxime prodrug of furamidine is
currently under phase III clinical trials as a trypanocidal
agent against human African trypanosomiasis (25,26).
These compounds have been well studied for their binding
to double-stranded DNA. Previous studies have shown
that furamidine binds duplex DNA in the DNA minor
groove selectively at AT rich sites [(A/T)4] (23,27,28).
Furamidine can also intercalate between GC base pairs of
duplex DNA (23,29,30). Furamidine could therefore
interfere with DNA processing enzymes such as Tdp1.
Because furamidine was able to inhibit Tdp1 activity
with a single-stranded DNA substrate and because of
its clinical relevance, we chose to study furamidine in
more detail.
Furamidine inhibits Tdp1 activity bothwith duplex and
single-stranded substratesbut ismore effective with the
duplex substrate
Having identiﬁed furamidine as a novel Tdp1 inhibitor, we
characterized its molecular eﬀect on Tdp1 activity using
gel-based assays (Figure 3) (18). Since both partially
duplex and single-stranded DNA are substrates for Tdp1
(2,19,31), we compared the inhibition of Tdp1 by
furamidine using the D14Y and 14Y substrates (sequences
as shown in Figure 3A) (18). As demonstrated in Figure 3
(panels B and C) furamidine inhibits the processing of
both the single and double-stranded substrates by Tdp1.
Since Tdp1 inhibition is slightly more eﬀective in the
duplex substrate (Figure 3B and C), DNA binding/
intercalation (23,29,30) may contribute to furamidine’s
potency. However, inhibition of Tdp1 activity by furami-
dine is also evident in a single-stranded substrate.
This is unlike aclarubicin, a known DNA intercalator
that inhibits Tdp1 selectively only with double-stranded
DNA (18). Thus, additional mechanism of Tdp1 inhibi-
tion by furamidine exists besides DNA intercalation or
minor groove binding.
Binding of furamidine to adouble-and single-stranded
substrate
We next evaluated the ability of furamidine to directly
interact with DNA in the absence of Tdp1. Surface
plasmon resonance (SPR) analyses were carried out using
single-stranded and double-stranded substrates (see
Materials and Methods section). As expected, Figure 4A
shows detectable binding of furamidine to duplex
oligonucleotide at submicromolar concentrations
(23,27–30,32). Furamidine rapidly reached a steady state
binding level with duplex DNA but then disassociated
more slowly. The equilibrium binding could only be ﬁt
using a two binding-site model with aﬃnities of 0.33 and
19mM (Figure 4C and equations described in the
Materials and Methods section). This seems reasonable
given that the sequence contains an AT rich site [(A/T)4]
within the duplex oligonucleotide, which corresponds to a
high aﬃnity-binding site for a heterocyclic diamidine
(23,27,28). The 14 base-pairs duplex probably also
support additional compound binding at lower aﬃnity
sites.
The binding of furamidine to a single-stranded sub-
strate was also examined by SPR. Figure 4B shows that
furamidine both associates with and dissociates from a
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Figure 2. Identiﬁcation of furamidine as a Tdp1 inhibitor by high-
throughput electrochemiluminescene assay. (A) Graph representing the
eﬀect of the 1981 compounds from the NCI-DTP diversity set on Tdp1
activity. Each dot indicates a signal value for a tested sample at 10mM
drug concentration. The substrate electrochemiluminescence (arbitrary
units) is lost in the presence of Tdp1 (‘n’ indicates the number of
samples). The eﬀect of 1981 compounds screened is represented.
Positive Tdp1 inhibitors prevent the loss of ECL signal. Dashed line
represents 50% inhibition of Tdp1 activity. Furamidine was among the
most potent compounds that inhibited Tdp1 activity. (B) Chemical
structure of furamidine.
4478 Nucleic Acids Research, 2007, Vol. 35, No. 13single-stranded substrate very rapidly in contrast with
what was observed for the duplex. This observation most
likely reﬂects the electrostatic interaction between the
phosphate backbone and the charged compound. We
estimate the Kd of furamidine to be  70mM with single-
stranded DNA (Figure 4D and equations described in the
Materials and Methods section). This result is in agree-
ment with the IC50 obtained for the same single-stranded
substrate (Figure 3C). To elucidate whether the inhibition
of Tdp1-mediated cleavage of the single-stranded DNA
substrate could be due to a stabilization of a hairpin
structure by furamidine, we plugged our sequence in the
mfold web application (http://bioweb.pasteur.fr/). The
most favorable folding option with three formed base
pairs, gave a G value of 0.32kcal/mol at 208C and a Tm
value of 13.68C, rendering this structure unstable under
our reaction conditions (258C). In addition, the fact that
we were able to measure a dissociation rate with the
duplex but not with the single-stranded oligonucleotide by
SPR leads us to believe that furamidine does not stabilize
any hairpin structure. We also evaluated the binding
of furamidine to amine-coupled Tdp1 protein (data
not shown) and found the interaction to be very weak
with aK d of 4900mM. Together, these experiments
demonstrate that furamidine does bind DNA with a
preference for a duplex substrate.
InhibitionofTdp1byfuramidineisindependentofthepresence
ofthymidines atthe 30-end ofthe substrate sequence
Furamidine has previously been shown to exhibit a strong
preference for A/T sequences (29,30). Since the co-crystal
studies showed Tdp1 interaction with the last 4nt at
the 30-end of the oligonucleotide substrate (33,34) and
those 4 bases were ACTT in our 14Y oligonucleotide, we
evaluated the eﬀect of altering the sequence of the
oligonucleotide substrate on the inhibition of Tdp1 by
furamidine. The terminal thymine dinucleotide (–TT) of
the 14Y oligonucleotide was replaced with a cytosine
dinucleotide(–CC)togeneratethe14Y-CColigonucleotide
(see Figure 5A). The ability of Tdp1 to process either the
14Y or 14Y-CC substrates was similar (Figure 5B and C).
Kinetic plot analysis shows the processing of either
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Figure 3. Inhibition of Tdp1 activity by furamidine. (A) Schematic representation of the Tdp1 biochemical assays. The partially duplex oligopeptide
D14Y or single-stranded 14Y were used as substrates.
32P-Radiolabeling (*) was at the 50 terminus of the 14-mer strand. Tdp1 catalyzes the
hydrolysis of the 30-phosphotyrosine bond and converts 14Y and D14Y to an oligonucleotide with 30-phosphate, 14P or D14P, respectively. (B)
Representative gel showing Tdp1 inhibition by furamidine with single strand (14Y) and partially duplex (D14Y) substrates. Reactions were
performed at 258C for 20min. Arrows indicate the 30-phosphate oligonucleotide product (14P) that runs quicker than the corresponding tyrosyl
oligonucleotide substrate (14Y) in a denaturing PAGE (18). The duplex D14Y substrate and D14P product are detected on the gel by their
corresponding labeled single strands (14Y and 14P), as they are no longer annealed under the denatured conditions. (C) Densitometry analysis of the
gel shown in panel B. Tdp1 activity was calculated as the percentage of 14Y converted to 14P as a function of the concentration of furamidine. The
horizontal line corresponds to 50% inhibition of Tdp1 activity.
Nucleic Acids Research, 2007, Vol. 35,No. 13 4479substrate almost completely within 10min of the reaction
time and at the same rate by 1ng of Tdp1 (Figure 5C).
Upon addition of varying concentrations of furamidine,
the processing of both the substrates 14Y and 14Y-CC by
Tdp1 was inhibited to the same degree (Figure 5D and E).
Thus, presence of a TT dinucleotide at the 30 terminus of
the DNA is not critical for Tdp1 inhibition by furamidine.
Furamidine inhibitsTdp1 more effectively thanberenil and
pentamidine
Structurally, furamidine can be considered as a bisbenza-
midine derivative (Figure 6A) (35) and belongs to a family
of diamidines (23). Of the several diamidines, berenil and
pentamidine are clinically active and used against parasitic
diseases (25,36–38). Though furamidine, pentamidine and
berenil share similarities in structure (Figure 6A), they
diﬀer in their central moiety being a furan unit for
furamidine, a triazene in berenil and a pentyldioxy chain
in pentamidine (represented by the ‘variable portion’ in
Figure 6A) (23).
To evaluate the contribution of the central furan
portion of furamidine for Tdp1 inhibition, we tested the
three analogs for their ability to inhibit Tdp1 activity.
Figure 6B shows that pentamidine did not inhibit Tdp1
activity under our assay conditions, and berenil showed
some activity, albeit at a high concentration (300mM).
Under the same conditions, furamidine exhibited an
inhibition of Tdp1 activity at 30mM (Figure 6B) and
therefore is the most potent of the three bisbenzamidines
examined.
Inhibition ofTdp1 by furamidine isdependent on both
reaction durationand Tdp1 concentration
The hallmark of reversible inhibitors is that when the
inhibitor concentration drops, enzyme activity is restored.
Our initial gel assays (Figure 3) were performed at a ﬁxed
time (20min) under conditions where Tdp1 almost
fully converted the substrate in the absence of inhibitor
(1ng, pH 8.0). We next evaluated how reaction time and
−50 50 100 150 200 250 0
Time (s)
−50 50 100 150 200 250 0
Time (s)
0
20
40
60
80
100
0
20
40
60
80
100
120
Furamidine (µM)
0.1 1 10
Furamidine (µM)
0.1 1 10
R
e
s
p
o
n
s
e
 
u
n
i
t
s
0
20
40
60
80
100
0
20
40
60
80
100
120
R
e
s
p
o
n
s
e
 
u
n
i
t
s
25µM
6.25µM
0.097µM
25µM
6.25µM
1.56µM
1.56µM
12.5µM
AB
CD
Figure 4. Binding of furamidine to a 495 response units surface of a stem-loop duplex oligonucleotide (A) and 504 response units surface of a single-
stranded oligonucleotide (B). The equilibrium level of binding was determined for each furamidine concentration for the duplex oligonucleotide
(C) or the single-stranded oligonucleotides (D). The graphs represent a ﬁt using a two binding-site model for the stem-loop duplex oligonucleotide
(C) or a single binding-site model for the single-stranded oligonucleotide (D). Twofold increments of furamidine concentration (0.097, 0.19, 0.39,
0.78, 1.56, 3.125, 6.25, 12.5 and 25mM) were used.
4480 Nucleic Acids Research, 2007, Vol. 35, No. 13Tdp1 concentration aﬀected furamidine’s ability to inhibit
Tdp1.
As shown in Figure 7A and B (A, left; and squares in
B), 1ng of Tdp1 converted  50% (t1/2) of the 14Y
substrate within  1.9min. Thus, we wished to determine
how furamidine aﬀected the kinetics of Tdp1 activity.
Tdp1 activity was slowed down as the concentration
of furamidine increased (Figure 7A). Kinetic plots
(Figure 7B) demonstrated that furamidine increased the
conversion half-time (t1/2) of the 14Y substrate from
1.9min in the absence of drug to 2.7min in the presence of
30mM furamidine (diamond in Figure 7B) and 4.4min in
the presence of 60mM furamidine (inverted triangle in
Figure 7B). Additionally, increasing Tdp1 concentration
was able to overcome Tdp1 inhibition by furamidine
(Figure 7C and D). The 50% inhibition of Tdp1 activity
observed by 30mM furamidine with 0.1ng of Tdp1 was
almost completely reversed by increasing the concentra-
tion of Tdp1 to 1ng (Figure 7C and diamond in
Figure 7D). Similar eﬀects were seen with 60mM and
250mM furamidine (Figure 7C and D). Thus, free Tdp1
competes with furamidine. Together, these results suggest
that furamidine produces reversible and competitive
inhibition of Tdp1.
DISCUSSION
Until now, Tdp1 activity has been measured by coupling a
30-phosphotyrosine to DNA or by isolating small peptide
fragments covalently linked to DNA, and resolving the
reaction product (30-phosphate DNA) from substrate in
polyacrylamide gel (1–3,8,34,39). In 2002, Cheng et al.
(40) used chromagenic substrates like the 30-(4-nitro)
phenyl phosphate DNA (40). However, spectrophoto-
metric detection of 4-nitrophenol required high concen-
trations of Tdp1 because of its relatively poor extinction
coeﬃcient. More recently, ﬂuorescence-based assays
have been designed using oligonucleotide and nucleo-
tide substrates containing 30-(4-methylumbelliferone)-
phosphate (DNA-MUP) (41). Tdp1-mediated cleavage
releases the 4-methylumbelliferone from the DNA, and
the resulting ﬂuorescence can be quantitated (41). Our
‘mix and read’ high-throughput electrochemiluminescent
(ECL) assay oﬀers two main advantages. First, the ECL
tag (BV-TAG) on the DNA substrate undergoes many
excitation/emission cycles, which amplify the output
signal, and increases sensitivity (Figure 1C). Since the
process is selective for the BV-Tag, the background signal
typical of ﬂuorescent methods is eliminated. Second,
positive hits are inferred by a gain/restoration of signal
as opposed to previous techniques that rely on loss of
signal, thereby providing high sensitivity and reliability.
More than 70% of the compounds identiﬁed by our
ECL screen at a single concentration were conﬁrmed as
inhibitors of Tdp1 by gel assays. Additionally, the ECL
assay is quick, as the high-throughput conﬁguration can
process a 96-well plate in  10min. Subsequent to screen-
ing the DTP diversity set by the ECL assay (Figure 2),
the antiparasitic furamidine (23) was identiﬁed as a
positive hit for Tdp1 inhibition and further characterized
by gel-based assays.
Our results demonstrate that furamidine inhibits the
activity of recombinant human Tdp1at low micromolar
concentrations both with single- and double-stranded
DNA substrates (see Figures 2A and 3B). Moreover, we
provide evidence that furamidine binds single-stranded
DNA (see Figure 4B and D). Our results also show that
furamidine exhibits no preference for a TT sequence over
a CC at the terminus of a single-stranded oligonucleotide
for Tdp1 inhibition (see Figure 5). Interestingly, another
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Nucleic Acids Research, 2007, Vol. 35,No. 13 4481diamidine, pentamidine was inactive against Tdp1
(see Figure 6) despite the fact that furamidine and
pentamidine have an overall similar structural curvature,
that closely matches the curvature of the DNA minor
groove (23). We also found that berenil was approxi-
mately one order of magnitude less eﬀective than
furamidine at inhibiting Tdp1. This suggests that the
furan linker in furamidine contributes to furamidine’s
inhibition of Tdp1 activity. We believe that DNA binding
is part of the furamidine’s mechanism of action. Further
studies such as crystallization will be required to fully
elucidate its complete mechanism of action. It is plausible
that furamidine could form a ternary complex by binding
at the interface created by the DNA substrate and the
enzyme (42,43).
To date, vanadate, tungstate, aminoglycoside antibio-
tics and ribosome inhibitors are the only known inhibitors
of Tdp1 (18,19). Though vanadate and tungstate bound
to Tdp1 provided insights into substrate binding
and catalytic mechanism of Tdp1 (19,44), they are general
inhibitors of a variety of enzymes involved in phosphoryl
transfer. Moreover, vanadate, tungstate, aminoglycoside
antibiotics and ribosome inhibitors inhibit Tdp1 activity
in biochemical assays only at high (millimolar) concentra-
tions (18). The present study demonstrates that furamidine
is by far the most potent inhibitor of Tdp1 reported to
date. However, determining the eﬀect of furamidine on
Tdp1 in cellular systems would be very hard to interpret as
furamidine may have additional target(s) because of its
DNA-binding activities. Nevertheless, furamidine presents
a prototype, to explore the possibility of generating
new chemotypes that would speciﬁcally target Tdp1.
Evaluation and characterization of other novel Tdp1
inhibitors identiﬁed by our ECL screen are ongoing. Our
present study with furamidine demonstrates that the ECL
assay is a useful tool for the high-throughput screening
of Tdp1 inhibitors.
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